bullish
Telix Pharmaceutical US ADS - Momentum Remains Strong, Offering Would Triple Its Cash Base
316 Views12 Jun 2024 11:00
Telix Pharmaceuticals (TLX AU) is looking to raise around US$190m in its US ADS listing. The bookrunners on the deal are Jefferies, Morgan Stanley, Truist Securities, and William Blair.
What is covered in the Full Insight:
- Deal terms and dynamics
- Updates since previous note
- Past deal performances
- Upcoming IPO and stock valuation
- Concluding thoughts
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Tamboran Resources US Offering - Strong Recent Momentum but CDIs Have Been Volatile Since Listing21 Jun 2024
- Telix Pharmaceutical US ADS - Momentum Remains Strong, Offering Would Triple Its Cash Base12 Jun 2024
- Telix Pharmaceutical US ADS - Past Deal Record Hasn't Been Strong, but Fortune Could Be Turning28 May 2024
- Super Hi International US ADS - Has Been Doing Well but Doesn’t Really Need the Cash30 Apr 2024
x